4 recruiting, 3 active not recruiting, 1 completed. 6 Phase 2, 5 Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Active not recruiting 3, Recruiting 3 |
| Phase 1 | 5 | Active not recruiting 3, Recruiting 2 |
| Not applicable | 1 | Completed 1 |
Follow MSI-H Cancer: new trials by email Literature Review of MSI-H Cancer trials Research Report on MSI-H Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer Iparomlimab and Tuvonralimab, First line chemotherapy plus PD-1/PD-L1 antibody - Gastric / Gastroesophageal Junction Adenocarcinoma, MSI-H Cancer | Phase 2 | Recruiting | Peking University | 106 | 2025-12-15 | 2026-08-05 |
| Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors MOMA-341, Irinotecan, Immunotherapy - Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 | Recruiting | MOMA Therapeutics | 132 | 2025-07-16 | 2026-07-23 |
| A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors. NDI-219216 - Advanced Solid Tumors Cancer, MSI-H Cancer | Phase 1 / Phase 2 | Recruiting | Nimbus Wadjet, Inc. | 134 | 2025-03-31 | 2026-05-06 |
| Open Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid Tumors Tiragolumab and atezolizumab - Head and Neck Neoplasms, MSI-H Cancer | Phase 2 | Recruiting | University Medical Center Groningen | 97 | 2023-10-18 | 2025-03-30 |
| Vascular Toxicities of Immune ChecKpoint Inhibitors : From Bed to Benchside Arterial Doppler for Flow Mediated Reserve measurement - Renal Cell Carcinoma, Bladder Cancer | Not applicable | Completed | Institut Mutualiste Montsouris | 39 | 2023-06-07 | 2026-04-08 |
| Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors Decoy20, Tislelizumab - Solid Tumor, Adult, HCC - Hepatocellular Carcinoma | Phase 1 / Phase 2 | Active not recruiting | Indaptus Therapeutics, Inc | 120 | 2023-02-28 | 2026-01-13 |
| A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies 23ME-00610 - Solid Tumor, Clear Cell Renal Cell Carcinoma | Phase 1 / Phase 2 | Active not recruiting | 23andMe, Inc. | 141 | 2021-12-29 | 2024-11-15 |
| A Beta-only IL-2 ImmunoTherapY Study MDNA11, Pembrolizumab (KEYTRUDA®) - Advanced Solid Tumor, Unresectable Solid Tumor | Phase 1 / Phase 2 | Active not recruiting | Medicenna Therapeutics, Inc. | 160 | 2021-08-27 | 2026-10-30 |
Carcinoma, Renal Cell (3) · Colorectal Neoplasms (3) · Carcinoma, Ovarian Epithelial (2) · Endometrial Neoplasms (2) · Fallopian Tube Neoplasms (2) · Melanoma (2) · Neoplasm Metastasis (2) · Neoplasms (2) · Stomach Neoplasms (2) · Urinary Bladder Neoplasms (2) · Atherosclerosis (1) · Carcinoma, Basal Cell (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Non-Small-Cell Lung (1)
Neoplasms by Site (6) · Neoplasms by Histologic Type (5) · Adenocarcinoma (4) · Carcinoma (4) · Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Neoplasms (4) · Neoplasms, Glandular and Epithelial (4) · Urogenital Diseases (4) · Urogenital Neoplasms (4) · Colonic Diseases (3) · Digestive System Diseases (3) · Digestive System Neoplasms (3) · Gastrointestinal Diseases (3) · Gastrointestinal Neoplasms (3)
Blood Specimen Collection (1) · Immunotherapy (1) · Interleukin-2 (1) · Irinotecan (1) · Tiragolumab (1) · atezolizumab (1) · pembrolizumab (1) · tislelizumab (1)
23andMe, Inc. (1) · Indaptus Therapeutics, Inc (1) · Institut Mutualiste Montsouris (1) · MOMA Therapeutics (1) · Medicenna Therapeutics, Inc. (1) · Nimbus Wadjet, Inc. (1) · Peking University (1) · University Medical Center Groningen (1)
United States (5) · Australia (3) · Canada (3) · France (2) · Ireland (2) · Portugal (2) · Spain (2) · China (1) · Netherlands (1) · South Korea (1) · Switzerland (1) · United Kingdom (1)
Anita Scheuber, MD, PhD (1) · Arash Yavari, MBBS (1) · Derk JA de Groot, MD PhD (1) · Nina Merchant (1)
2023 (1)